Cardiovascular Systems Inc (CSII)fresh off their merger with Replidyne is scheduled to release their Q3 earnings on May 6. The Executive management team has recently undergone some changes and their are rumors that the sales force reps have been forced into a lower commissioned performance arrangement.
A new collaborative distribution agreement with Invatec was presented as a way to enhance the portfolio of CSII. The CSII sales force will now distribute a small vessel platform of PTA balloon, one of which is the amphirion .014 system. It seems like where this is headed is now the physician will be encouraged to follow athrectomy with the diamondback with PTA using one of this series of balloons. Thats somewhat odd since the premise of athrectomy is that its better than PTA. That would seem to be a bait and switch to say that PTA is no good so use our diamondback athrectomy device and then after you use it, now that we carry balloons- just touch it up with one of our very effective balloon products. It all adds up to a costly intervention with as yet unproven benefit
From Tradingmarkets.com
Cardiovascular Systems, Inc. (CSI), a medical device company developing and commercializing interventional treatment systems for vascular disease, announced that Brian Doughty has been promoted to vice president of commercial operations from vice president of marketing, and Scott Kraus, previously a senior sales director, has been named vice president of sales.
Doughty and Kraus will assume responsibilities previously performed by John Borrell, who has left the company to pursue other opportunities. Additionally, the company announced that Dr. Nabil Dib, MSc, FACC, has been appointed to serve as medical advisor to CSI.
"These promotions recognize the outstanding work and abilities of Brian and Scott," said David L. Martin, CSI president and chief executive officer. "Together, they have nearly 30 years of medical device industry experience. They have the skills, experience and drive to implement marketing and sales strategies to accelerate adoption of our Diamondback 360 degrees Orbital Atherectomy System for peripheral arterial disease, as well as lead a growing national sales organization of over 100 professionals. We also want to thank John Borrell for his many contributions to CSI. John played an important role in building our sales organization and launching our Diamondback 360o system."
Doughty came to CSI in November 2006 as director of marketing and was named vice president of marketing in August 2007. Prior to joining CSI, he served as director of marketing at EKOS, a manufacturer of an endovascular treatment system for vascular clots; before that, he worked in practice development at FoxHollow Technologies. In addition, he held various sales and sales management positions at Medtronic and Johnson & Johnson.
Kraus has been with CSI since September 2006, most recently as a senior sales director. Previously, he held sales management positions with Boston Scientific Corp., Guidant and C.R. Bard. Earlier, he gained sales experience at C.R. Bard, Bristol-Myers Squibb and Surgical Specialties Corp.
Dr. Nabil Dib to Serve as Medical Advisor
Comments